BioSpace News Archive

Pieris Pharmaceuticals, Inc. reported financial results for the third quarter of 2022 ended September 30, 2022, and provided an update on the Company’s recent and anticipated future developments.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 2,000 shares of KalVista common stock on November 1, 2022 as inducement material to such employee entering into employment with KalVista.

Sensei Biotherapeutics, Inc. today announced that John Celebi, President and Chief Executive Officer, will present at the 13th Annual Jefferies Global Healthcare Conference, being held in London, United Kingdom, on Thursday, November 17, 2022, at 7:25 a.m. GMT.

Rhythm Pharmaceuticals, Inc. announced positive Phase 2 results and long-term extension trial data in hypothalamic obesity that are being presented as a late-breaking poster at The Obesity Society’s ObesityWeek® 2022 conference in San Diego.

CNS Pharmaceuticals, Inc. today announced the first patient in Europe has been enrolled and dosed in France in the Company’s ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

Simulations Plus, Inc today announced that, through a joint proposal with the University of Florida’s College of Pharmacy it has been awarded a new funded contract from the U.S. Food and Drug Administration (FDA) to advance in vitro and (patho)physiology-based pharmacokinetics (PBPK) models to understand and predict pulmonary absorption and tissue retention of inhaled drugs.

NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that it will report its financial results for the third quarter of 2022 after the market closes on November 8, 2022.

Turn Biotechnologies today announced it has appointed Richard “Ric” Peterson as chief financial officer.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of an interim analysis of the Phase 4 REFINE-ALS study, designed to identify predictive and pharmacodynamic biomarkers to measure the effect of RADICAVA® (edaravone) in people with amyotrophic lateral sclerosis (ALS).

AbCellera (Nasdaq: ABCL) announced today that Regeneron has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with AbCellera as part of a multi-target collaboration between the companies, into further preclinical development.